NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Iksuda Therapeutics

Iksuda Therapeutics

Private
Newcastle upon TyneHealthcare & Life Scienceshttps://www.iksuda.com/

Last Round

Strategic

Jun 15, 2025

Est. Valuation

$93.98M

Total Funding Raised

$68.75M

Company Overview

Iksuda Therapeutics is a clinical-stage biotechnology company that specializes in the development of next-generation Antibody-Drug Conjugates (ADCs) for treating cancers with high unmet needs.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

ADCantibody-drug conjugatestargeted cancer therapybioconjugationoncology drug developmentlinker technologycytotoxic payloadclinical-stage biotechprecision medicinedrug licensingnext-gen oncologybiotech pipelinecancer drug discovery

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Iksuda Therapeutics Comps

Public and private peers based on sector, stage, and business model.

Iksuda Therapeutics comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Iksuda Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
StrategicJun 15, 2025
Corporate FundingMar 21, 2025
StrategicNov 15, 2024
Series AJun 7, 2021
GrantJun 6, 2017
Grant
Jul 27, 2015

Key People

Founding team and executive leadership

David Simpson

CEO

Executive Team

Iksuda Therapeutics Investors

Notable investors and investment history

Iksuda Therapeutics investors
InvestorRounds
LigaChem BiosciencesCorporate Funding, Strategic
IP GroupSeries A, Seed
North East Access to FinanceSeed
Premier PartnersSeries A
Mirae Asset SecuritiesSeries A
Centre for Process InnovationGrant
Innovate UKGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 8, 2026

    Presenting data at the 2026 ASCO Gastrointestinal Cancers Symposium in San Francisco.

  • Jan 6, 2026

    Early analyses of IKS014 activity to be presented at ASCO GI Cancers Symposium.

Iksuda Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Iksuda Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Iksuda Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersNewcastle upon Tyne
Employee Range43
Year Founded2007
Last FundingJun 15, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.